Treatment Landscape of Low-Risk Myelodysplastic Syndrome (MDS)

Join us for this insightful episode of the Clinical Insights segment, where we dived deep into the complexities of low-risk myelodysplastic syndrome (MDS). The focus of the discussion was community medical oncologists, and we were joined by Dr. Amer Zeidan from Yale University, Dr. Tiffany Tanaka from UCSD, Dr. Jamile Shammo from Northwestern University, and Dr. Christopher Benton from Rocky Mountain Cancer Center. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9... Apple Podcast: https://podcasts.apple.com/us/podcast... Follow us on social media: •⁠ ⁠X/Twitter:   / oncbrothers   •⁠ ⁠Instagram:   / oncbrothers   •⁠ Website: https://oncbrothers.com/ In this episode, we explored: • The definition and significance of low-risk MDS • The importance of accurate diagnosis and initial workup, including cytogenetics and NGS • Risk stratification using the IPSS-M scoring system • Treatment options, including the role of erythropoietin-stimulating agents and Luspatercept in frontline settings • Key findings from the MEDALIST and COMMANDS trials • Patient management strategies, including dosing, side effects, and quality of life considerations Whether you're a healthcare professional or someone interested in learning more about MDS, this episode provides valuable insights into the latest advancements in treatment and patient care. Subscribe to our channel for more episodes and updates on the latest in oncology! #LowRiskMDS, #MyelodysplasticSyndrome, #MEDALIST, #COMMANDS, #ClinicalInsights